TY - JOUR
T1 - A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition
AU - Koshy, Anita G.
AU - Daver, Naval G.
AU - Fathi, Amir T.
N1 - Funding Information:
AK does not report any relevant conflicts of interest. ND reports consulting fees from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Celgene, AbbVie, Agios, Amgen, Astellas, Genentech, Immunogen, Jazz, Forty Seven, Trovagene, Gilead, Kite, Trillium, and research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Karyopharm, Servier, Genentech, ImmunoGen, Novimmune, Incyte, AbbVie, Astellas, Forty Seven, Gilead, FATE therapeutics, Trovagene, Novartis. ATF reports consulting fees from Boston Biomedical, PTC Therapeutics, Agios, Celgene/Bristol-Myers Squibb, Abbvie, Astellas, Novartis, Daiichi Sankyo, Trovagene, Seattle Genetics, Amgen, Pfizer, NewLink Genetics, Jazz, Takeda, Genentech, Blueprint, Kura Oncology, Kite, Amphivena, Trillium, Forty Seven/Gilead, and research funding from Celgene/BMS, Seattle Genetics, Takeda, and Agios.
Publisher Copyright:
© 2020
PY - 2020/12
Y1 - 2020/12
N2 - Acute myeloid leukemia (AML) remains a therapeutically challenging malignancy with high rate of relapse and poor outcomes. There has been increased understanding of the molecular characteristics of AML and the various roles of the immune system in its pathogenesis, the result of which has led to the study and development of multiple immune-based approaches for this disease. In this review, we aim to provide an overview of the recent advancements made in antibody-based approaches to the treatment of AML including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibition. In addition, we provide insight and discuss the promise of these agents, some of which may soon enter the therapeutic armamentarium we currently employ against this lethal disease.
AB - Acute myeloid leukemia (AML) remains a therapeutically challenging malignancy with high rate of relapse and poor outcomes. There has been increased understanding of the molecular characteristics of AML and the various roles of the immune system in its pathogenesis, the result of which has led to the study and development of multiple immune-based approaches for this disease. In this review, we aim to provide an overview of the recent advancements made in antibody-based approaches to the treatment of AML including monoclonal antibodies, antibody-drug conjugates, and immune checkpoint inhibition. In addition, we provide insight and discuss the promise of these agents, some of which may soon enter the therapeutic armamentarium we currently employ against this lethal disease.
KW - Acute myeloid leukemia
KW - Antibody-based therapies
KW - Immune checkpoint inhibition
UR - http://www.scopus.com/inward/record.url?scp=85095602663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095602663&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2020.101220
DO - 10.1016/j.beha.2020.101220
M3 - Review article
C2 - 33279176
AN - SCOPUS:85095602663
SN - 1521-6926
VL - 33
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 4
M1 - 101220
ER -